Zentalis Pharmaceuticals, Inc. (ZNTL) intrinsic value & 10-year financials
Zentalis Pharmaceuticals, Inc. (ZNTL) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 8 fiscal years revenue reached to $0, with an average return on invested capital of -15.8%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $2.13
- Market cap
- $153.1M
- Revenue (FY2025)
- $0
- ROIC (10-yr avg)
- -15.8%
- Free cash flow (FY2025)
- -$125.2M
ZNTL 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $0 | -$137.1M | -$1.91 | -$125.2M | — | -54.7% |
| FY2024 | $67.4M | -$165.8M | -$2.33 | -$171.1M | -283.6% | -48.1% |
| FY2023 | $0 | -$292.2M | -$4.47 | -$208.4M | — | -67.3% |
| FY2022 | $0 | -$236.8M | -$4.48 | -$166.3M | — | -57.8% |
| FY2021 | — | -$158.7M | $0.00 | -$160.2M | — | -68.8% |
| FY2020 | — | -$117.8M | $0.00 | -$87.6M | — | -42.5% |
| FY2019 | — | -$45.7M | -$1.63 | -$39.5M | — | 228.6% |
| FY2018 | — | — | — | — | — | — |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
Zentalis Pharmaceuticals, Inc. revenue growth over the past decade is N/A; insufficient history prevents a reliable 10-year CAGR calculation.
Zentalis Pharmaceuticals, Inc. has historically struggled to out-earn its cost of capital, averaging just -48.1% ROIC.
Zentalis Pharmaceuticals, Inc. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Zentalis Pharmaceuticals, Inc. is evaluated under Benjamin Graham's defensive framework using SEC EDGAR fundamentals using an 8.5 + 2g earnings multiple and a 5.1% AAA bond-yield baseline.